#Bristol-Myers Squibb sued for $6.4B over delayed cancer drug
“#Bristol-Myers Squibb sued for $6.4B over delayed cancer drug” Bristol-Myers Squibb was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene, which the drugmaker bought in 2019. According to a complaint in Manhattan federal court, Bristol-Myers failed to use contractually required “diligent efforts”…